Kineta, Inc. (KA)
NASDAQ: KA · IEX Real-Time Price · USD
0.610
-0.015 (-2.37%)
At close: Apr 26, 2024, 4:00 PM
0.630
+0.020 (3.25%)
After-hours: Apr 26, 2024, 5:17 PM EDT
Kineta Revenue
In the year 2023, Kineta had annual revenue of $5.44M with 178.65% growth.
Revenue (ttm)
$5.44M
Revenue Growth
+178.65%
P/S Ratio
1.23
Revenue / Employee
$494,727
Employees
11
Market Cap
6.69M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 5.44M | 3.49M | 178.65% |
Dec 31, 2022 | 1.95M | -7.14M | -78.52% |
Dec 31, 2021 | 9.09M | 2.20M | 31.83% |
Dec 31, 2020 | 6.90M | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 2.84M | -2.50M | -46.83% |
Dec 31, 2017 | 5.34M | -3.04M | -36.30% |
Dec 31, 2016 | 8.38M | 4.07M | 94.43% |
Dec 31, 2015 | 4.31M | -838.00K | -16.27% |
Dec 31, 2014 | 5.15M | 4.01M | 351.36% |
Dec 31, 2013 | 1.14M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionKA News
- 19 days ago - Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial - GlobeNewsWire
- 5 weeks ago - Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 weeks ago - KVA12123 Clears Additional Cohorts in Monotherapy and in Combination Therapy Arms in the Phase 1/2 VISTA-101 Clinical Trial; Initial Clinical Response Data Reported - GlobeNewsWire
- 2 months ago - Kineta Announces Restructuring and Exploration of Strategic Alternatives - GlobeNewsWire
- 2 months ago - Kineta to Present New Preclinical Data on its Anti-VISTA Antibody KVA12123 in Acute Myeloid Leukemia at the AACR Blood Cancer Discovery Symposium - GlobeNewsWire
- 2 months ago - Kineta to Present at Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Kineta to Participate in H.C. Wainwright Virtual @Home Fireside Chat Series - GlobeNewsWire
- 3 months ago - Kineta Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors - GlobeNewsWire